In the industry news section of this week’s episode, we kick things off with Tamarind Bio’s efforts to develop user-friendly artificial intelligence tools for science researchers. Then we examine the impact of the U.S. Food and Drug Administration’s reversal on its earlier refusal to review Moderna’s mRNA vaccine for the flu, discuss Gilead’s acquisition of Arcellx to expand its cancer therapy pipeline, and dive into Takeda’s investment in Vir Biotech’s prostate cancer candidate. Then on the research front, we get into the science behind new protein-like polymers engineered to target and degrade some of cancer’s most challenging driver proteins. And we discuss a potential control switch for CAR T cells that could make these immunotherapies much safer.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for Biology
By Fay Lin, PhD, GEN Edge, February 24, 2026
StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine Companies
By Alex Philippidis, GEN Edge, February 21, 2026
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline
By Alex Philippidis, GEN Edge, February 23, 2026
Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration
By Alex Philippidis, GEN, February 26, 2026
New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving Cancer
GEN, February 11, 2026
Drug-Controlled CAR T Cells May Enable Safer Immunotherapy
GEN, February 23, 2026
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
